Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.

ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapy entails the genetic engineering of a patient's T-cells to express membrane spanning fusion receptors with defined specificities for tumor-associated antigens. These CARs are capable of eliciting robust T-cell activation to initiate killing of the target tumor cells. This therapeutic approach has produced unprecedented clinical outcomes in the treatment of "liquid" hematologic cancers, but to date has not produced comparable responses in targeting solid malignancies. Advances in our understanding of the immunobiology of solid tumors have highlighted several hurdles which currently hinder the efficacy of this therapy. These barriers include the insufficient accumulation of CAR T-cells in the tumor due to poor trafficking or physical exclusion an

SUBMITTER: Kosti P 

PROVIDER: S-EPMC5972325 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature